<DOC>
	<DOCNO>NCT00474266</DOCNO>
	<brief_summary>The purpose study demonstrate , 12-23 month old child , non-inferiority meningococcal vaccine 134612 give Priorix-Tetra™ . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Safety &amp; Immunogenicity Study Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ 12-23 Month-Old Children</brief_title>
	<detailed_description>Open multicentre study 4 treatment group . Two group receive 134612 vaccine Priorix-Tetra™ either different visit follow second Priorix-Tetra™ vaccination 84 day . Two control group receive Priorix-Tetra™ Meningitec™ different visit follow second Priorix-Tetra™ vaccination 84 day . For subject , two blood sample take : prior 42 day first vaccination . In subset ( 30 % subject Groups A en C ) select study centre : additional sample 42 day second Priorix-Tetra™ dose .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol . A male female , include , 12 23 month age time vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Previously complete routine childhood vaccination best parent ' legal guardian ' knowledge . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccine dose . Planned administration/ administration vaccine foreseen study protocol within one month 42 day first dose vaccine ( ) . Previous vaccination meningococcal vaccine serogroup A , C W and/or Y . History meningococcal disease . Previous vaccination measles , mumps , rubella , and/or varicella . History measles , mumps , rubella and/or varicella . Known exposure measles , mumps , rubella , varicella zoster within 30 day prior vaccination . Any confirm suspected immunosuppressive immunodeficient condition ( congenital secondary ) , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine , include neomycin . Major congenital defect serious chronic illness . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MMRV vaccine</keyword>
	<keyword>co-administration</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>meningococcal vaccine</keyword>
	<keyword>conjugate vaccine</keyword>
</DOC>